Corvert Side Effects
Generic Name: ibutilide
Note: This page contains information about the side effects of ibutilide. Some of the dosage forms included on this document may not apply to the brand name Corvert.
Not all side effects for Corvert may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.
For the Consumer
Applies to ibutilide: parenteral solution for injection
Side effects include:
Generally well tolerated. Adverse events affecting the cardiovascular system (e.g., arrhythmogenic affects, affects on cardiac conduction, palpitation, hypotension, hypertension), nausea, and headache reported in ≤5.1% of patients.
For Healthcare Professionals
Applies to ibutilide: intravenous solution
Cardiovascular side effects were experienced by 25% of 586 patients in clinical trials. Like many other antiarrhythmic agents, ibutilide (the active ingredient contained in Corvert) is potentially proarrhythmic. Ibutilide can induce sustained polymorphic ventricular tachycardia (VT) in 1.7% to 8.3% and nonsustained polymorphic VT in 1.7% to 2.7% of patients. Sustained monomorphic VT (0.2%), bundle branch block (1.9%), ventricular extrasystoles (5.1%), supraventricular extrasystoles (0.9%), hypotension or postural hypotension (2.0%), bradycardia or sinus bradycardia (1.2%), nodal arrhythmia (0.7%), congestive heart failure (0.5%), tachycardia or sinus tachycardia or supraventricular tachycardia in (2.7%), idioventricular rhythm (0.2%), hypertension (1.2%), QT segment prolongation in (1.2%), and syncope (0.3%) have been reported in patients receiving ibutilide therapy. The incidence of these events, except for syncope, was greater in treated patients compared with placebo.
Ibutilide can cause potentially fatal arrhythmias, particular sustained polymorphic ventricular tachycardia (VT), usually in association with QT prolongation (torsades de pointes), but sometimes without documented QT prolongation. In clinical studies, these arrhythmias, which require cardioversion, occurred in 1.7% of treated patients during or within a number of hours of use of ibutilide. These arrhythmias can be reversed if treated promptly. It is essential that ibutilide be administered in a setting of continuous ECG monitoring and by personnel trained in identification and treatment of acute ventricular arrhythmias, particularly polymorphic VT.
Patients with atrial fibrillation of more than 2 to 3 days' duration must be adequately anticoagulated, generally for at least 2 weeks.
Patients with chronic atrial fibrillation have a strong tendency to revert after conversion to sinus rhythm and treatments to maintain sinus rhythm carry risks. Patients to be treated with ibutilide should be carefully selected such that the expected benefits of maintaining sinus rhythm outweigh the immediate risks of ibutilide and the risks of maintenance therapy, and benefits are likely to offer an advantage compared with alternative management.
Gastrointestinal side effects appear limited to nausea in 1.9% of patients (compared with 0.8% with placebo).
Nervous system side effects include headache in 3.6% of patients (compared with 3.1% with placebo).
Renal failure has been reported in 0.3% of patients. A causal relationship has not been established.
Dermatologic side effects including a case of dermatologic erythematous bullous lesions due to contact with ibutilide (the active ingredient contained in Corvert) has been reported. Ibutilide fumarate contains a methanesulfonamide moiety.
A medical student exposed to a 10 mL spill of ibutilide (0.017 mg/mL in 5% dextrose) immediately towel dried the exposed hands. Several hours elapsed before the hands were washed in soap and water. Six to eight hours postexposure the student noted a tingling and burning sensation on the hands and at 18 hours the areas of hand exposed to ibutilide were erythematous and red, with 2 bullous lesions on each hand. A single dose of topical betamethasone (0.05%) was applied and the areas were kept clean and dry. Resolution occurred after approximately 10 days. Rechallenge was refused.
More about Corvert (ibutilide)
Related treatment guides
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.